Dissolution Testing for Canadian Generic Drug Submissions: What Health Canada Reviewers Actually Check

Of all the analytical data packages reviewed inside an Abbreviated New Drug Submission (ANDS), dissolution is the section that generates the most Health Canada information requests. Not because companies skip the tests — most don’t. The breakdown almost always happens at the methodological level: wrong apparatus selection, incomplete pH profiles, or an f2 similarity factor calculated on data that reviewers simply won’t accept.

Health Canada’s dissolution expectations draw from both ICH Q6A and the agency’s own Dissolution Testing and Acceptance Criteria for Immediate-Release Solid Oral Dosage Form Drug Products Containing High Solubility Drug Substances guidance. But there’s enough Canadian-specific interpretation layered on top that teams relying purely on FDA precedent sometimes find themselves rewriting their methods mid-submission. Here’s what the science actually requires — and where most ANDS sponsors leave points on the table.

Building a Dissolution Method That Health Canada Will Accept

Method development for dissolution isn’t a formality — it’s where you make or break the downstream comparison work. Health Canada expects sponsors to use compendial apparatus where a USP or Ph.Eur. monograph exists for the reference product. In practice, that typically means Apparatus 1 (basket, 100 rpm) or Apparatus 2 (paddle, 50 or 75 rpm). Apparatus 3 and 4 are acceptable for modified-release or poorly soluble compounds when scientifically justified, but plan to defend that choice explicitly.

Media selection is where submissions run into trouble most often. For an immediate-release (IR) solid oral dosage form, you need to run profiles across a minimum of three media conditions: 0.1 N HCl (pH 1.2), acetate buffer (pH 4.5), and phosphate buffer (pH 6.8). Each profile requires at least 12 units, and sampling must be dense enough to characterize the full dissolution curve — typically 15, 30, 45, and 60 minutes, with an additional early time point (5 or 10 min) if rapid release is expected.

One detail that catches teams off guard: Health Canada explicitly expects the discriminatory medium — the medium you’re proposing for the release specification — to be identified and justified during development, not after the comparative work is done. If your proposed specification medium is pH 6.8 but the drug shows near-complete dissolution at pH 1.2 within 15 minutes, you’ll need to explain why pH 6.8 is the more meaningful quality control anchor. That justification has to be prospective and science-based, not retrospective.

Surfactants can be added to dissolution media for poorly soluble drugs, but Health Canada reviewers scrutinize their use closely. The type, concentration, and scientific basis for inclusion should be documented, and surfactant concentration should be minimized to the level that achieves discriminatory sensitivity without artificially inflating release rates.

Dissolution Profile Comparisons and the f2 Similarity Factor

Once method development is complete, the comparative dissolution profile (CDP) package drives most of the technical conversation with Health Canada. The f2 similarity factor is the primary statistical tool, and the threshold is unambiguous: an f2 value ≥ 50 (on a 0–100 scale) indicates sufficient similarity between the test and reference product profiles.

But the rules around calculating f2 are strict, and three conditions regularly disqualify datasets.

Only one time point above 85% dissolution can be used. If both the test and reference products reach ≥85% dissolved by 15 minutes, only a single time point from that plateau region is permitted in the calculation. Teams that include two or three time points where both products have plateaued end up with a distorted — usually artificially high — f2 value. Health Canada reviewers flag this consistently.

The f2 calculation must use mean values from individual units, not pooled vessel data. The coefficient of variation for the reference product time points included in the calculation should be ≤10% at early time points and ≤5% at later time points. High variability in reference product data can invalidate the f2 approach altogether, pushing you toward model-independent distance methods or a Mahalanobis distance approach instead.

Twelve units per product, per medium, per time point. This is non-negotiable under Health Canada’s Canada GMP framework and the agency’s comparative bioavailability guidance (GUI-0036). Submissions that arrive with n=6 dissolution profile data because the team “ran two vessels per time point” will be returned. It’s a persistent and entirely avoidable deficiency.

When f2 cannot be applied — due to high variability, non-linear dissolution profiles, or rapid dissolution in all tested media — Health Canada accepts alternative model-independent approaches. The key is documenting why f2 isn’t applicable before defaulting to an alternative, not after a reviewer raises the objection.

BCS-Based Biowaivers: What’s Available Under Canadian Guidelines

Since Health Canada adopted ICH M9 (Biopharmaceutics Classification System-based Biowaivers) in 2021, more ANDS sponsors have been exploring whether their drug substance qualifies for a biowaiver — demonstrating bioequivalence through dissolution data alone, without a clinical study in human subjects.

Under ICH M9, biowaivers are available for BCS Class I drugs (high solubility, high permeability) and, under specific conditions, BCS Class III drugs (high solubility, low permeability). The solubility classification requires the drug substance’s highest clinical dose to dissolve completely in 250 mL of aqueous media across the pH 1.2–6.8 range at 37°C. For permeability, Class I status typically requires human intestinal permeability data, Caco-2 data, or a well-justified literature basis tied to an established reference compound.

For BCS Class III biowaivers, the bar is higher. Health Canada and ICH M9 expect very rapid dissolution — ≥85% in 15 minutes across all three pH media — for both test and reference. And excipient differences between the test and reference product must be carefully justified. Any excipient known to affect GI transit or permeability — surfactants, osmotic agents, bile sequestrants — will need specific attention.

One thing worth being realistic about: BCS classification data submitted in support of a biowaiver is scrutinized intensely. Solubility data generated at room temperature rather than 37°C, or permeability data from non-validated cell lines, tends not to survive review. The investment in generating rigorous BCS data upfront is almost always less costly than defending inadequate data once reviewer questions arrive.

Common Deficiencies That Delay ANDS Approvals

Based on Health Canada’s published reviewer guidance and the patterns we see in submission support work, these are the dissolution-related deficiencies that appear most consistently in Canadian ANDS packages.

Inadequate method validation. ICH Q2(R1) validation applies to dissolution methods as much as to any other analytical procedure. Specificity, linearity, accuracy, and precision at the dissolution acceptance limit are the minimum set. Submissions that present “qualification” data rather than full validation — or that omit intermediate precision entirely — draw immediate scrutiny under health canada GMP review criteria.

Mismatched reference product lots. The reference product used for comparative dissolution profiling should ideally be the same lot used in any clinical bioequivalence study included in the dossier. When lots differ, Health Canada expects data demonstrating that the dissolution behaviour of the lots is comparable. A single-lot reference product profile submitted without any lot qualification is a gap reviewers notice.

Incomplete pH profile data. Submitting profiles only at the specification medium pH and excluding pH 1.2 or 4.5 data because “the drug is stable in that range” won’t satisfy reviewers. All three standard pH conditions are expected for IR solid oral dosage forms unless a compelling scientific rationale is provided for omission — and that rationale needs to appear in the submission, not in a response to a clarification letter.

Specification limits not anchored to the clinical batch. Health Canada expects dissolution acceptance criteria to be set with reference to the dissolution profile of the clinical bioequivalence batch. An acceptance criterion of Q ≥ 80% at 30 minutes is common, but it must reflect what the bio-batch actually achieves — not simply adopted from a USP monograph without verification against your specific formulation.

No demonstrated discriminatory capability. The guidance asks sponsors to show that the dissolution method can detect meaningful formulation changes. If you’ve never challenged your method with batches differing in compression force, disintegrant level, or particle size distribution, you haven’t demonstrated discrimination. This gap often surfaces during GMP inspections under Canada’s Food and Drug Regulations (C.02.019–C.02.028) rather than in paper review, but it belongs in the validation package from the start.

Getting the Dissolution Package Right the First Time

Dissolution packages that hold up through Health Canada review share one characteristic: they were built with the reviewer’s questions in mind from the start. The f2 criteria, the three-medium requirement, the 12-unit minimum, the BCS data standards — these aren’t procedural hurdles. They’re the scientific framework for demonstrating that a generic product will perform the same way in patients as the reference product it’s meant to replace.

If your dissolution data were generated using FDA precedents as the primary reference, reconcile that data against Health Canada’s specific guidance documents before filing. The differences are subtle in some areas and significant in others, and they’re worth resolving before a reviewer finds them.

---

Written by Nour Abochama, Quality & Regulatory Advisor, Androxa. Learn more about our team

Talk to our team about Health Canada compliance Contact us

Related from our network

• Analytical Method Validation and Laboratory Testing Services — ISO 17025-accredited method validation and testing for regulatory submissions across North America.
• Pharmaceutical Product Registration in the EU — Guidance on EMA and national competent authority requirements for drug product approvals in European markets.